Who are Daratumumab/rHuPH20's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Darzalex Faspro, Darzalex, DARATUMUMAB (DARZALEX®), Daratumumab Hyaluronidase-fihj, SARCLISA, Daratumumab and corticosteroid treatment.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/daratumumab-rhuph20.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Daratumumab/rHuPH20 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Daratumumab/rHuPH20 (Daratumumab/rHuPH20) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Monoclonal antibody with recombinant human hyaluronidase. Area: Oncology.

phase 3 Monoclonal antibody with recombinant human hyaluronidase CD38 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Daratumumab/rHuPH20 (Daratumumab/rHuPH20) — Masonic Cancer Center, University of Minnesota. Daratumumab is a monoclonal antibody that targets CD38 on multiple myeloma cells, while rHuPH20 is a recombinant human hyaluronidase that enhances subcutaneous delivery by breaking down hyaluronic acid in the extracellular matrix.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Daratumumab/rHuPH20 TARGET	Daratumumab/rHuPH20	Masonic Cancer Center, University of Minnesota	phase 3	Monoclonal antibody with recombinant human hyaluronidase	CD38
Darzalex Faspro	daratumumab-and-hyaluronidase-fihj	Pfizer	marketed	CD38-directed Cytolytic Antibody [EPC]	CD38	2020-01-01
Darzalex	daratumumab	Johnson & Johnson	marketed	Monoclonal antibody	CD38	2015-01-01
DARATUMUMAB (DARZALEX®)	DARATUMUMAB (DARZALEX®)	Hospices Civils de Lyon	marketed	CD38-targeting monoclonal antibody	CD38
Daratumumab Hyaluronidase-fihj	Daratumumab Hyaluronidase-fihj	Memorial Sloan Kettering Cancer Center	marketed	CD38-targeting monoclonal antibody	CD38
SARCLISA	ISATUXIMAB-IRFC	SANOFI AVENTIS US	marketed	CD38-directed Cytolytic Antibody [EPC]	Lymphocyte differentiation antigen CD38
Daratumumab and corticosteroid treatment	Daratumumab and corticosteroid treatment	Institute of Hematology & Blood Diseases Hospital, China	marketed	Monoclonal antibody (CD38-targeting) combined with corticosteroid	CD38

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Monoclonal antibody with recombinant human hyaluronidase class)

Masonic Cancer Center, University of Minnesota · 1 drug in this class
National Cancer Institute (NCI) · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Daratumumab/rHuPH20 — Competitive Intelligence Brief. https://druglandscape.com/ci/daratumumab-rhuph20. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab